



I just returned from #WoCoVa16 in Lisbon. What a meeting! Representatives from over 60 countries, 1000 participants and so much interest in improving all aspects of device safety – from selection, insertion, care and maintenance” Chopra (2016).

Vineet Chopra writes in the [ImprovePICC.com](http://ImprovePICC.com) blog “I just returned from #WoCoVa16 in Lisbon. What a meeting! Representatives from over 60 countries, 1000 participants and so much interest in improving all aspects of device safety – from selection, insertion, care and maintenance. My heartiest congratulations to the organizers for arranging such a fantastic scientific session.

ReTweet if useful... Vineet Chopra discusses an evidence debate at #WoCoVa16  
[@ivteam #ivteam](http://ctt.ec/Ufb97+)

Click To Tweet

On a personal note – it was also nice to finally meet many of the people I have corresponded with via email, putting faces to names and shaking hands after all these years. I also appreciated the many different aspects of vascular access in the world. It’s fascinating to me how the same device is often inserted by different people, cared for in different ways, and viewed upon variably based upon these and other factors. For those of you that have never been to WoCoVa, I highly encourage it — it is refreshing and opens your eyes to important differences in our practice.

One of the highlights of the meeting for me was debates with key leaders regarding the evidence. At many sessions that I attended, there was a palpable anxiety regarding the evidence base and whether or not it applies to current practice. Most notably, I heard the revered Drs. Pittiruti and Lamberti (both of whom I have tremendous respect for), speak about systematic reviews and meta-analysis and the limitations of current data. While I understood their concerns, I also was vexed regarding their interpretation of these studies that have been published in top-tier journals. In particular, they discussed our recent meta-analysis regarding PICC DVT published in the Lancet. I had the opportunity to challenge some of their assertions in an unscripted mini-debate.

### **Full Discussion**

**Thank you to our partners for supporting IVTEAM**

